Novo Nordisk presented data at the EASD congress held in Vienna, Austria.
1 report, 1 independent
Updated Sep 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk presented data at the EASD congress held in Vienna, Austria.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Austria
country in Central Europe
Related events
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- Novo Nordisk leadership undergoes changes amidst intensifying competition in the GLP-1 market, involving companies like Eli Lilly and Orion.
- Novo Nordisk launched insulin in the US market.
- Novo Nordisk was a major engine of Denmark's growth, but a hiring freeze was raising concerns among policymakers on August 22, 2025.
- Novo Nordisk operates in Europe, North America, the Middle East, and mainland China, while MarketBeat covers both Novo Nordisk and Eli Lilly.
Coverage
Newest first; wire copies grouped- GlobeNewswireNovo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress The INFORM real-world evidence study